SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GZMO
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mike McFarland who wrote (87)9/16/1999 10:04:00 AM
From: jeffbas  Read Replies (1) of 438
 
Mike my point in using "non-scientist" is that despite the very complete description of SAGE given on the web site, which sounds like
a super tool (with customers), unless you have actually worked in the industry as a scientist using these tools you have no idea whether the market cap given to AFFX versus GZMO is because SAGE is no good by comparison; just as good but not as commercialized YET; a great, narrow application research tool that gives GZMO a real research edge; or primarily due to differing Wall Street recognition of essentially similar technologies.

I have been trying to elicit an opinion from the people who might know without any success. The answer could make a lot of difference in whether GZMO is moving toward fair valuation (adding in cancer vaccine therapy and Folkman) or has long since left it.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News